Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms

Kebede Hussein, Omar Abdel-Wahab, Terra L. Lasho, Daniel L. Van Dyke, Ross L. Levine, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


TET2 is a putative tumor suppressor gene located at chromosome 4q24. TET2 mutations were recently described in several myeloid neoplasms but correlations with cytogenetic findings have not been studied. Among a recently described cohort of patients with myeloproliferative neoplasms (MPN) who underwent TET2 mutation analysis, 199 had information on karyotype at diagnosis or time of TET2 testing: 71 polycythemia vera (PV), 55 primary myelofibrosis (PMF), 43 essential thrombocythemia (ET), 13 post-PV MF, 7 post-ET MF, and 10 blast phase MPN. Forty eight patients (24%) exhibited abnormal karyotype: 15 favorable (sole 20q-, 13q-, or +9), 8 unfavorable (complex karyotype or sole +8), and 25 "other" cytogenetic abnormalities. We found no significant difference either in the incidence or type of cytogenetic abnormalities between TET2 mutated (n = 25) and unmutated (n = 174) cases. Seventy nine patients, including 14 with TET2 mutations, underwent follow-up cytogenetic testing and the findings were again not affected by TET2 mutational status. We conclude that TET2 mutated MPN patients are not cytogenetically different than their TET2 unmutated counterparts.

Original languageEnglish (US)
Pages (from-to)81-83
Number of pages3
JournalAmerican journal of hematology
Issue number1
StatePublished - Jan 2010

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this